Evidence map›Paper›PMID 36687263›Full record

ArticleScandinavian journal of child and adolescent psychiatry and psychology2022

Psychiatric Diagnoses and Medications in Wolfram Syndrome.

Angela M Reiersen, Jacob S Noel, Tasha Doty, Richa A Sinkre, Anagha Narayanan, Tamara Hershey

Open access · diamondAbstract read
In one paragraph

Article in Scandinavian journal of child and adolescent psychiatry and psychology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Angela M ReiersenDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
Jacob S NoelDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
Tasha DotyDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
Richa A SinkreDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
Anagha NarayananDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
Tamara HersheyDepartment of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States.
Washington University in St. Louis · USMedical College of Wisconsin · USThe University of Texas Health Science Center at San Antonio · US

Funding

TRACKING NEURODEGENERATION IN EARLY WOLFRAM SYNDROMER01HD070855 · NICHD · WASHINGTON UNIVERSITY · PI HERSHEY, TAMARA G · 2012 to 2022
$5.6M
NICHD NIH HHS R01 HD070855
6 · The paper itself

Abstract

Background: Wolfram Syndrome is a rare genetic disorder usually resulting from pathogenic variation in the Objective: To examine lifetime psychiatric diagnoses and medication history in Wolfram Syndrome. Method: Child, adolescent, and young adult Wolfram Syndrome participants (n=39) were assessed by a child & adolescent psychiatrist to determine best estimate DSM-5 lifetime psychiatric diagnoses as well as psychoactive medication history. In addition, the Child & Adolescent Symptom Inventory-5 (CASI-5) Parent Checklist was used to determine likely psychiatric diagnoses based on symptom counts in Wolfram Syndrome patients (n=33), type 1 diabetes (n=15), and healthy comparison (n=18) groups. Results: Study participants with Wolfram Syndrome had high lifetime rates of anxiety disorders (77%). Also, 31% had an obsessive-compulsive spectrum disorder, 33% had a mood disorder, 31% had a neurodevelopmental or disruptive behavior disorder, and 31% had a sleep-wake disorder. More than half of Wolfram Syndrome participants had taken at least one psychoactive medication, and one third had taken at least one selective serotonin reuptake inhibitor (SSRI). Some individuals reported poor response to sertraline but better response after switching to another SSRI (fluoxetine or citalopram). In general, people with Wolfram Syndrome often reported benefit from psychotherapy and/or commonly used psychoactive medications appropriate for their psychiatric diagnoses. Conclusions: Wolfram Syndrome may be associated with elevated risk for anxiety and obsessive-compulsive spectrum disorders, which seem generally responsive to usual treatments for these disorders.

Indexed as

AnxietyER stressmedicationObsessive Compulsive DisorderPsychiatryWolfram Syndrome

Identifiers

PMID36687263
PMCPMC9828213
OpenAlexW4313323731

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.